AlphaRx, Inc.

Vansolin formulation completed for treatment of infectious diseases

Published in Lab Law Weekly, October 21st, 2005

AlphaRx, Inc., (ALRX.OB) has completed the development of a novel antibiotic formulation using its patent pending solid lipid nanoparticle delivery platform.

The new product is announced under the trade name Vansolin. The active ingredient is Vancomycin, a very powerful antibiotic used mainly in hospitals to treat life threatening infectious disease such as hospital acquired pneumonia, ventilator associated pneumonia and severe sepsis. Vansolin is the company's fourth product employing nanotechnology, a line of products which are intended to increase the efficacy of the existing base drug compounds while reducing their side effects.

Vancomycin was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2005-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry